Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
These are not trivial objections
Shreeram Aradhye, M.D., President of Development and Chief Medical Officer at Novartis, emphasized the need for effective treatments in this debilitating condition and called the trials a significant milestone toward addressing it
Patients describe quick turnaround on questions, thorough explanations during consultations, and genuine engagement with their progress rather than cookie-cutter responses
Mol Cell
aeruginosa are expected to become resistant to fluoroquinolones, aminoglycosides, and beta-lactam antibiotics
US$ 22.85
US$ 23.47
US$ 20.71
US$ 28.32
US$ 27.37
